Therefore 57% are positive. SAGE Therapeutics has $11000 highest and $18 lowest target. Zooming out to the 50-Day Simple Moving Average, we can see a difference of -11.34% from current stock levels. On Wednesday, December 14 the stock rating was upgraded by Raymond James to "Strong Buy". The firm now has a "buy" rating on the biopharmaceutical company's stock. Including today's unusual volume, Sage Therapeutics, Inc.'s stock is performing at 49.63% on the year. The stock has "Neutral" rating by Goldman Sachs on Wednesday, March 30. H.C. Wainwright maintained the stock with "Hold" rating in Friday, August 4 report. Cowen & Co maintained the shares of SAGE in report on Tuesday, September 5 with "Buy" rating. The firm has "Buy" rating by BMO Capital Markets given on Tuesday, June 27. In recent session, Sage Therapeutics, Inc. Leerink Swann has "Buy" rating and $9700 target. The company was downgraded on Wednesday, February 22 by H.C. Wainwright.
Vanda Pharmaceuticals Inc.is a biopharmaceutical company. The company has market cap of $5.29 billion. The Firm is focused on the development and commercialization of therapies to address unmet medical needs. It now has negative earnings. The stock rose 0.13% or $0.1 reaching $76.5. Equities analysts predict that Sage Therapeutics will post ($7.38) earnings per share for the current year. It has outperformed by 99.75% the S&P500.
Investors sentiment increased to 1.19 in Q4 2016.
Since May 11, 2017, it had 0 buys, and 1 insider sale for $568,100 activity. Sold All: 17 Reduced: 41 Increased: 59 New Position: 27. Moreover, Swiss Bancorporation has 0% invested in SAGE Therapeutics Inc (NASDAQ:SAGE). Baker Bros Advisors LP invested in 0.1% or 208,328 shares. It dropped, as 60 investors sold VZ shares while 658 reduced holdings. Volume is simply the number of shares or contracts that trade over a given period of time, usually a day. Bnp Paribas Arbitrage Sa holds 1.11 million shares.
WARNING: "Sage Therapeutics, Inc". Sphera Funds Mngmt Ltd has 90,000 shares. This is the signal from the 20-day MA which is used to monitor changes in share price.
US Issues Visa Restrictions to Eritrea, Guinea
The Trump administration has put heavy diplomatic pressure on countries that resist accepting deportees. Eritrea faces the toughest sanctions of the four countries.
SAGE has been the subject of several other research reports. Bamco New York owns 0.03% invested in SAGE Therapeutics Inc (NASDAQ:SAGE) for 88,320 shares. Principal Fincl Grp Inc stated it has 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE).
SAGE Therapeutics, Inc.is a clinical-stage biopharmaceutical company. A stock rating will usually tell the investor how well a stock's market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The Firm is engaged in developing and commercializing medicines to treat central nervous system disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Ratings analysis reveals 100% of Vanda Pharma's analysts are positive. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The Lower end of the earnings estimate is $-2.09, while the higher end of the earnings estimate is $-1.7.
SAGE Therapeutics Inc. (NASDAQ: SAGE) share prices fell heavily after the company disclosed that its Phase 3 STATUS trial of brexalonone in super-refractory status epilepticus (SRSE) did not meet its primary endpoint. Analyst mean recommendation for this stock stands at 1.70.